CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income	$ 154,547	$ 175,013
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	10,192	15,395
Deferred tax expense	1,732	5,945
Equity compensation	9,679	6,572
Loss on debt extinguishment	0	22,107
Net (gains) losses on investments and other financial instruments	7,698	772
Change in certain assets and liabilities:
Accrued investment income	628	1,502
Reinsurance recoverable on loss reserves	(4,521)	2,188
Reinsurance recoverable on paid losses	17,936	36,072
Premium receivable	625	(798)
Deferred insurance policy acquisition costs	965	133
Profit commission receivable	9,324	6,779
Loss reserves	527	(32,250)
Unearned premiums	(11,822)	(12,575)
Return premium accrual	(1,300)	(900)
Current income taxes	39,481	38,445
Other, net	(23,405)	(36,389)
Net cash provided by (used in) operating activities	212,286	228,011
Cash flows from investing activities:
Purchases of investments	(229,198)	(94,017)
Proceeds from sales of investments	32,991	218,373
Proceeds from maturity of fixed income securities	131,389	225,972
Additions to property and equipment	(363)	(888)
Net cash provided by (used in) investing activities	(65,181)	349,440
Cash flows from financing activities:
Purchase of convertible junior subordinated debentures	0	(56,965)
Repayment of FHLB Advance	0	(155,000)
Cash portion of loss on debt extinguishment	0	(22,107)
Repurchase of common stock	(76,151)	(123,640)
Dividends paid	(30,096)	(26,112)
Payment of withholding taxes related to share-based compensation net share settlement	(7,199)	(8,688)
Net cash provided by (used in) financing activities	(113,446)	(392,512)
Net increase (decrease) in cash and cash equivalents and restricted cash and cash equivalents	33,659	184,939
Cash and cash equivalents and restricted cash and cash equivalents at beginning of period	332,913	304,958
Cash and cash equivalents and restricted cash and cash equivalents at end of period	$ 366,572	$ 489,897